The Tumultuous Terrain of Oncology Finance

This chapter examines the declining investments in oncology and a pivotal incident involving Sarepta Therapeutics' gene therapy, Elevitus, which faces significant regulatory scrutiny. As the FDA calls for a halt on the therapy’s shipments amidst safety concerns, the financial and emotional implications for the biotechnology company and the Duchenne community become evident.